NHAS
CORT icon

Novo Holdings A/S’s Corcept Therapeutics CORT Stock Holding History

Novo Holdings A/S’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,411,362
Closed -$112M – 38
2024
Q3 		$112M Hold
2,411,362
– – 5.54% 5
2024
Q2 		$78.3M Hold
2,411,362
– – 4.22% 7
2024
Q1 		$60.7M Hold
2,411,362
– – 4.19% 5
2023
Q4 		$78.3M Sell
2,411,362
-966,406
-29% -$26.5M 4.84% 6
2023
Q3 		$92M Hold
3,377,768
– – 6.8% 4
2023
Q2 		$75.2M Hold
3,377,768
– – 5.81% 4
2023
Q1 		$73.2M Hold
3,377,768
– – 4.83% 5
2022
Q4 		$68.6M Buy
3,377,768
+50,000
+2% +$1.25M 4.28% 7
2022
Q3 		$85.3M Buy
3,327,768
+801,278
+32% +$21.4M 4.07% 6
2022
Q2 		$60.1M Buy
+2,526,490
New +$55M 2.96% 11

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Novo Holdings A/S's CORT Position: Q4 2024 in Review

Novo Holdings A/S sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 2,411,362 shares — an estimated $112M sold.

Novo Holdings A/S first reported a position in CORT in Q2 2022 and held it in 10 quarters. The position peaked at $112M in Q3 2024. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Novo Holdings A/S reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Novo Holdings A/S sold 2,411,362 Corcept Therapeutics shares in Q4 2024, an estimated $112M.
  • Novo Holdings A/S first reported a position in Corcept Therapeutics in Q2 2022 and held it in 10 quarters.
  • Novo Holdings A/S's Corcept Therapeutics position peaked at $112M in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.